Safety Information
OLUX Foam is a super-potent topical corticosteroid indicated for short-term topical treatment of the inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp, and for short-term topical treatment of mild to moderate plaque-type psoriasis of non-scalp regions excluding the face and intertriginous areas.
Treatment beyond 2 consecutive weeks is not recommended and the total dosage should not exceed 50 g per week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis. In a controlled pharmacokinetic study, some subjects experienced reversible suppression of the adrenals following 14 days of OLUX Foam therapy.
Use in children under 12 years of age is not recommended.
In a controlled clinical trial (188 subjects) with OLUX Foam in subjects with psoriasis of the scalp, there were no localized scalp adverse reactions reported in the OLUX Foam treated subjects. In two controlled clinical trials (360 subjects) with OLUX Foam in subjects with psoriasis of non-scalp regions, localized adverse events that occurred in the OLUX Foam treated subjects included application site burning (10%), application site dryness (<1%), and other application site reactions (4%).
Rebate Offer
Instantly save up to $35 off your OLUX® Foam prescription (even works with copay).
Patient Information Brochure
Download this helpful patient information brochure to learn more about OLUX and scalp dermatoses.